SCHEMBL1395407

SCHEMBL1395407

FC(F)(F)COc1nc(NCc2ccc(-c3ccc(Oc4ccccc4)cc3)cc2)nc(Nc2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDH2 P48735 9/20 0.51
LMNA P02545 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SLC2A1 P11166 1/20 0.49
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
CFTR P13569 2/20 0.45
APP P05067 1/20 0.44
AURKA O14965 1/20 0.42
KCNH3 Q9ULD8 2/20 0.42
PDGFRB P09619 1/20 0.41
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
CDK11B P21127 1/20 0.41
FLT3 P36888 1/20 0.41
CDKL2 Q92772 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1395248 0.94 LMNA (0.48) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL1391768 0.90 APP (0.57) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL1395285 0.89 IDH2 (0.53) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL10244329 0.89 IDH2 (0.61) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL1395426 0.89 APP (0.53) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL10244570 0.88 IDH2 (0.51) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL1395442 0.88 IDH2 (0.53) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL1392581 0.88 IDH2 (0.53) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL1395431 0.87 MAPT (0.53) IDH2LMNAMEN1KMT2ATDP1
SCHEMBL1392019 0.87 IDH2 (0.57) IDH2LMNAMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS IDH2 1936/4885LMNA 3218/4885MEN1 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.